Scientific advisory board Member
Scientific advisory board
Ernst Wagner is professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität (LMU) Munich since 2001 and member of the Center for Nanoscience (CeNS). He coordinates ‘Biomedical Nanotechnologies’ of the Cluster of Excellence ‘Nanosystems Initiative Munich (NIM)’.After a Ph.D. in Organic Chemistry from the Technical University of Vienna and a postdoctoral stay at the ETH Zurich, in 1987 he became Group Leader at the Institute of Molecular Pathology (IMP) and at the Vienna University Biocenter, developing synthetic gene transfer systems. In parallel, 1992-2001 he was Director for Cancer Vaccines at Boehringer Ingelheim Austria, where he developed the first-in-world polymer-based clinical gene therapy study (an IL-2 gene-modified cancer vaccine) in 1994. His current research focuses on precise sequence-defined drug and protein carriers, and receptor-targeted delivery of nucleic acid therapeutics including pDNA, siRNA, or microRNA. The biomedical focus resides on tumor-targeted delivery and therapy, overcoming mechanisms of chemoresistance.rnst Wagner has authored ≥397 publications (current h-index 70). He is an Editor of Pharmaceutical Research and Editor-in Chief of the Journal of Gene Medicine, Board member of the German Society for Gene Therapy, Committee member of the ASGCT, and has been Board of Scientific Advisor member of the Controlled Release Society. He has been Honorary Guest Professor at Utrecht University, at Fudan University (Shanghai), and at Sichuan University (Chengdu).
Pharmaceutical Biotechnology, Biomedical science